FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.

SLU-PP-332 is a relatively recent addition to the metabolic research compound landscape. Developed at the Saint Louis University laboratory of Thomas Burris, with foundational medicinal-chemistry work published from 2020 and the compound’s pan-ERR agonist characterization published in 2023, SLU-PP-332 entered the research market as one of the first reported small-molecule pan-agonists of the estrogen-related receptor (ERR) family (Billon et al., 2023). ERR signaling has been a subject of metabolic and mitochondrial research for more than two decades, but the development of selective ERR agonists has been historically limited, making SLU-PP-332 a notable pharmacological tool for mechanistic work on this receptor family.

This article describes the ERR receptor family that SLU-PP-332 acts on, the structural and pharmacological features of the compound, the metabolic pathway research it has been used to investigate, and the verification infrastructure relevant to research material.

Research Snapshot

• SLU-PP-332 is a small molecule compound developed at Saint Louis University and characterized as a pan-agonist of the estrogen-related receptor (ERR) family. The compound’s characterization as an ERR agonist was published in 2023 (Billon et al., 2023), with earlier medicinal-chemistry foundation work from 2020.
• The ERR family comprises three receptor subtypes (ERRα, ERRβ, ERRγ), and SLU-PP-332 has been characterized as a synthetic agonist of all three. The published potency hierarchy is ERRα-preferential: EC50 ≈ 98 nM at ERRα, ≈ 230 nM at ERRβ, and ≈ 430 nM at ERRγ in cell-based reporter assays (Billon et al., 2023). The compound is best described as an ERRα-preferential pan-agonist rather than equipotent across the family.
• Preclinical research has investigated SLU-PP-332 in rodent models for effects on mitochondrial biogenesis, oxidative capacity in skeletal muscle, exercise performance, and metabolic adaptation, a profile that has placed the compound within the broader category of “exercise mimetic” research candidates.
• The compound binds the ligand-binding domain of the ERR receptors and stabilizes a transcriptionally active conformation that promotes recruitment of coactivators including PGC-1α (Mootha et al., 2004, for the foundational PGC-1α/ERRα work).
• Pure Health Peptides offers SLU-PP-332 in Capsule format and Vial format. Material is sourced from qualified third-party manufacturers; the verification chain, independent lot-level testing by Ethos Analytics under ISO/IEC 17025 accreditation, is what Pure Health Peptides owns and stands behind across the catalog.

Introduction

SLU-PP-332 is a relatively recent addition to the metabolic research compound landscape. Developed at the Saint Louis University laboratory of Thomas Burris, with foundational medicinal-chemistry work published from 2020 and the compound’s pan-ERR agonist characterization published in 2023, SLU-PP-332 entered the research market as one of the first reported small-molecule pan-agonists of the estrogen-related receptor (ERR) family (Billon et al., 2023). ERR signaling has been a subject of metabolic and mitochondrial research for more than two decades, but the development of selective ERR agonists has been historically limited, making SLU-PP-332 a notable pharmacological tool for mechanistic work on this receptor family.

This article describes the ERR receptor family that SLU-PP-332 acts on, the structural and pharmacological features of the compound, the metabolic pathway research it has been used to investigate, and the verification infrastructure relevant to research material.

The ERR Receptor Family

The estrogen-related receptors are a family of three orphan nuclear receptors, ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3), named for their structural similarity to the classical estrogen receptors (ERα and ERβ). Despite the structural relationship, ERRs do not bind estrogen or natural estrogen-related compounds, and they have remained classified as orphan receptors because no endogenous ligand has been firmly established. ERR signaling is regulated instead through receptor expression levels, post-translational modifications, and the activity of transcriptional coregulators such as PGC-1α (Giguère, 2008).

ERRα has been the most extensively characterized of the three subtypes (Audet-Walsh & Giguère, 2015). The receptor is expressed across tissues with high mitochondrial demand, skeletal muscle, cardiac muscle, brown adipose tissue, kidney, and liver, and has been identified as a master transcriptional regulator of oxidative metabolism. Target genes of ERRα include components of the electron transport chain, fatty acid oxidation enzymes, and regulators of mitochondrial biogenesis. The receptor works closely with PGC-1α as a transcriptional coactivator in the regulation of mitochondrial gene expression programs (Mootha et al., 2004).

ERRβ and ERRγ have been characterized in additional tissue contexts. ERRβ has been investigated in embryonic stem cell biology and in inner ear development. ERRγ has been characterized as a regulator of cardiac metabolism and oxidative gene expression, with research focus on its role in fetal-to-adult metabolic transitions and in heart function research models (Misra, Kim & Choi, 2017).

Across the three subtypes, ERR activity is closely tied to mitochondrial function and oxidative energy metabolism. This positioning has made the ERR family a focal point in metabolic research aimed at understanding the transcriptional control of mitochondrial bioenergetics.

SLU-PP-332 as a Pan-ERR Agonist

SLU-PP-332 emerged from structure-activity research conducted at Saint Louis University aimed at developing small-molecule agonists of the ERR family. Prior to its characterization, the field had relied predominantly on ERR inverse agonists and antagonists (such as XCT790 for ERRα) for mechanistic work, with limited agonist tools available. The development of SLU-PP-332 as a synthetic agonist therefore filled a gap in the ERR pharmacology toolkit (Billon et al., 2023).

In receptor binding studies, SLU-PP-332 has been characterized as activating all three ERR subtypes, ERRα, ERRβ, and ERRγ, with a clear potency hierarchy. The published characterization reports EC50 values of approximately 98 nM at ERRα, 230 nM at ERRβ, and 430 nM at ERRγ in cell-based reporter assays. SLU-PP-332 is therefore best described as an ERRα-preferential pan-agonist rather than an equipotent agent across the receptor family. This hierarchy matters mechanistically because much of the published research on SLU-PP-332’s metabolic effects has been attributed to ERRα engagement, which is also the receptor subtype most extensively characterized in the broader metabolic literature.

The mechanism of action involves direct binding to the ligand-binding domain of the ERR receptors, stabilizing the receptor in a transcriptionally active conformation that promotes recruitment of coactivators including PGC-1α. The downstream consequence in research models has been increased expression of ERR target genes, particularly those involved in mitochondrial biogenesis and oxidative metabolism (Billon et al., 2023).

Metabolic Pathway Research and the Exercise Mimetic Hypothesis

The most extensive research literature on SLU-PP-332 has focused on its metabolic effects in preclinical models. In rodent studies, the compound has been investigated for effects on mitochondrial biogenesis in skeletal muscle, oxidative capacity, fatty acid oxidation, glucose handling, and exercise performance. The pattern of observed effects in these models has positioned SLU-PP-332 within the broader category of “exercise mimetic” research compounds, a label applied to small molecules that produce metabolic adaptations resembling those induced by endurance exercise training, without the exercise stimulus itself.

In skeletal muscle research models, SLU-PP-332 exposure has been associated with increased mitochondrial content, upregulation of oxidative phosphorylation gene expression, and enhanced fatty acid oxidation capacity. These effects have been linked mechanistically to ERRα activation and the downstream coordination of mitochondrial biogenesis through the PGC-1α / ERRα transcriptional axis (Billon et al., 2023; Mootha et al., 2004).

In exercise capacity assays, rodent models exposed to SLU-PP-332 have demonstrated increased treadmill running performance and improved endurance metrics. The observed effects have been most pronounced in mouse models examining sub-maximal exercise capacity and time-to-exhaustion endpoints, consistent with adaptations in oxidative muscle function.

Beyond the skeletal muscle context, SLU-PP-332 research has also touched on cardiac metabolism (where ERRγ has a substantial role), adipose tissue biology (where ERRα regulates oxidative metabolism in brown adipose tissue), and broader systemic metabolic outcomes. The breadth of ERR expression across metabolically active tissues has made SLU-PP-332 a versatile tool for mechanistic investigation across multiple research domains.

Sourcing, Verification, and Lot-Level Testing

SLU-PP-332 in the Pure Health Peptides catalog is sourced from qualified third-party manufacturers as strictly compliant research material. Pure Health Peptides does not manufacture material directly. What Pure Health Peptides owns and stands behind across the catalog is the third-party verification chain.

Every production lot is independently tested by Ethos Analytics under ISO/IEC 17025 accreditation, with the result published as a lot-specific Certificate of Analysis. The standard COA panel reports compound identity verified by HPLC and mass spectrometry per USP <621>, purity, quantity, heavy metals screening by ICP-MS per USP <233>, endotoxin testing per USP <85>, and microbiological screening per USP <61> and USP <62>. Lot-level COAs are accessible through the publicly browsable COA Library (Vial COAs | Capsule COAs | Liquid COAs).

SLU-PP-332 is available in two carrier formats: a Capsule format for solid-dose research workflows where reconstitution is not required, and a Vial format for workflows requiring reconstitution at the point of use. Both formats follow identical lot-level COA discipline, with each carrier verified independently as part of the release protocol.

The Direction of SLU-PP-332 Research

SLU-PP-332 research continues to develop, with active investigation into the structural basis of ERR receptor activation, the tissue-specific consequences of ERRα-preferential pan-ERR agonism, and the relationship between ERR-mediated transcriptional programs and broader metabolic adaptation. The compound’s positioning as one of the first small-molecule pan-ERR agonists makes it an active reference point in the receptor pharmacology literature. The exercise mimetic research direction in particular continues to attract investigation, both as a tool for understanding the transcriptional underpinnings of exercise-induced metabolic adaptation and as a candidate for further characterization in preclinical metabolic research models.

FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.

Frequently Asked Research Questions

What is SLU-PP-332, and what receptor does it act on?

SLU-PP-332 is a synthetic small molecule developed at Saint Louis University, characterized as a pan-agonist of the estrogen-related receptor (ERR) family, ERRα, ERRβ, and ERRγ. The compound is ERRα-preferential, with EC50 ≈ 98 nM at ERRα, ≈ 230 nM at ERRβ, and ≈ 430 nM at ERRγ in cell-based reporter assays (Billon et al., 2023).

What is the difference between estrogen-related receptors and estrogen receptors?

The estrogen-related receptors (ERRs) are named for their structural similarity to the estrogen receptors (ERα and ERβ), but they do not bind estrogen and have remained classified as orphan receptors. ERR activity is regulated through expression levels, post-translational modification, and the activity of coregulators such as PGC-1α, rather than through ligand binding by an endogenous hormone.

Why is SLU-PP-332 considered an exercise mimetic in research models?

In preclinical models, SLU-PP-332 exposure has been associated with metabolic adaptations resembling those induced by endurance exercise, increased mitochondrial biogenesis in skeletal muscle, upregulation of oxidative phosphorylation gene expression, enhanced fatty acid oxidation capacity, and improved exercise performance in rodent models. The label “exercise mimetic” is applied to compounds that produce these adaptations without the exercise stimulus itself.

What carrier formats is SLU-PP-332 available in at Pure Health Peptides?

SLU-PP-332 is offered in Capsule format (for solid-dose research workflows) and Vial format (for workflows requiring reconstitution). Both formats follow the standard lot-level COA discipline applied across the Pure Health Peptides catalog.

Where is SLU-PP-332 in the Pure Health Peptides catalog sourced from?

SLU-PP-332 is sourced from qualified third-party manufacturers as strictly compliant research material. Pure Health Peptides does not manufacture material directly. The third-party verification chain, independent ISO/IEC 17025-accredited testing of every production lot, is what Pure Health Peptides owns and stands behind.

References

Scientific Literature

• Billon, C., et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology.
• Audet-Walsh, É. & Giguère, V. (2015). The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta Pharmacologica Sinica, 36(1), 51–61.
• Misra, J., Kim, D.K., & Choi, H.S. (2017). ERRγ: A junior orphan with a senior role in metabolism. Trends in Endocrinology and Metabolism, 28(4), 261–272.
• Giguère, V. (2008). Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocrine Reviews, 29(6), 677–696.
• Mootha, V.K., et al. (2004). Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression. Proceedings of the National Academy of Sciences, 101(17), 6570–6575.

Regulatory and Pharmacopeial Standards

• United States Pharmacopeia. Chapter <621>: Chromatography.
• United States Pharmacopeia. Chapter <233>: Elemental Impurities, Procedures.
• United States Pharmacopeia. Chapter <85>: Bacterial Endotoxins Test.
• United States Pharmacopeia. Chapter <61>: Microbiological Examination of Nonsterile Products, Microbial Enumeration Tests.
• United States Pharmacopeia. Chapter <62>: Microbiological Examination of Nonsterile Products, Tests for Specified Microorganisms.
• International Organization for Standardization. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories.